HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudolph, M. G. Articles by Eisen, H. N. Search for Related Content PubMed PubMed Citation Articles by Rudolph, M. G. Articles by Eisen, H. N.

A Peptide That Antagonizes TCR-Mediated Reactions with Both Syngeneic and Allogeneic Agonists: Functional and Structural Aspects¹

Markus G. Rudolph^2,3,, Lucy Q. Shen^*, Stephen A. Lamontagne^*, John G. Luz, Joseph R. Delaney^*, Qing Ge^*, Bryan K. Cho^*, Deborah Palliser^*, Carol A. McKinley^*, Jianzhu Chen^*, Ian A. Wilson^3, and Herman N. Eisen^3,*

^* Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and Department of Molecular Biology and Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037

We identify and consider some characteristics of a peptide antagonist for the Ag-specific receptor on 2C cells (the 2C TCR). The peptide, GNYSFYAL (called GNY), binds to H-2K^b, and a very high-resolution crystal structure of the GNY-K^b complex at 1.35 Å is described. Although the GNY peptide does not bind to L^d, the potency of GNY-K^b as an antagonist is evident from its ability to specifically inhibit 2C TCR-mediated reactions to an allogenic agonist complex (QLSPFPFDL-L^d), as well as to a syngeneic agonist complex (SIYRYYGL-K^b). The crystal structure and the activities of alanine-substituted peptide variants point to the properties of the peptide P4 side chain and the conformation of the Tyr-P6 side chain as the structural determinants of GNYSFYAL antagonist activity.

This article has been cited by other articles:

				E. J. Adams, Z. S. Juo, R. T. Venook, M. J. Boulanger, H. Arase, L. L. Lanier, and K. C. Garcia Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors PNAS, June 12, 2007; 104(24): 10128 - 10133. [Abstract] [Full Text] [PDF]

				L. K. Ely, K. J. Green, T. Beddoe, C. S. Clements, J. J. Miles, S. P. Bottomley, D. Zernich, L. Kjer-Nielsen, A. W. Purcell, J. McCluskey, et al. Antagonism of Antiviral and Allogeneic Activity of a Human Public CTL Clonotype by a Single Altered Peptide Ligand: Implications for Allograft Rejection J. Immunol., May 1, 2005; 174(9): 5593 - 5601. [Abstract] [Full Text] [PDF]

				D. Palliser, E. Guillen, M. Ju, and H. N. Eisen Multiple Intracellular Routes in the Cross-Presentation of a Soluble Protein by Murine Dendritic Cells J. Immunol., February 15, 2005; 174(4): 1879 - 1887. [Abstract] [Full Text] [PDF]